Firm Launches Investigation Against Altimmune and Certain Officers and/or Directors for Possible Breaches of Fiduciary Duty and Other Possible Violations of State and/or Federal Law
Introduction to the Altimmune Investigation
In connection to the Altimmune class action lawsuit, the Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for nearly 25 years, is investigating whether certain officers and directors of Altimmune, Inc. (NASDAQ: ALT) breached their fiduciary duties to shareholders and the Company. Find out more by visiting our Investigations Page.
Background to the Altimmune Investigation
Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity, metabolic, and liver diseases.
The Altimmune class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to the results of Altimmune’s IMPACT Phase 2b metabolic associated steatohepatitis (“MASH”) trial; (ii) Altimmune failed to meet an important statistical significance marker relating to the fibrosis reduction primary endpoint; and (iii) Altimmune concealed higher responses in the placebo group, which defendants knew or should have known would negatively impact the IMPACT Phase 2b MASH trial’s topline results.
The Altimmune class action lawsuit further alleges that on June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH and disclosed that “[a]lthough we saw positive trends in fibrosis improvement, statistical significant was not achieved on this endpoint.”
On this news, the price of Altimmune stock fell more than 53%, according to the complaint.
Damage to Altimmune, Inc.
As a result of the foregoing, the company lost over half of its market capitalization and has been sued by its shareholders in federal court for violating the federal securities laws for which the Company will have to pay substantial compensation to defend, and may face a judgment or settlement in the millions of dollars which the Company will be required to pay. The investigation seeks to determine whether Altimmune’s executive officers and/or directors breached their fiduciary duties to the Company and its stockholders and/or committed other violations of state and/or federal law.
Altimmune Shareholders Urged to Contact the Firm
If you purchased or are a holder of Altimmune securities, have information, or have any questions concerning this announcement or your rights or interests with respect to these matters, including the Altimmune Investigation, please contact Timothy L. Miles, Esquire, at 855-846-6529, or by email at [email protected]. If you inquire by email, please include your mailing address, telephone number, and the number shares owned.
More additional information on the Altimmune investigation, please visit our Investigations Page.
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
